BCMA, BAFF-R (TNFRSF13C), TACI (TNFRSF13B)

Class

Allogeneic CAR-T cell therapy (multi-antigen construct targeting all three plasma-cell-survival TNF receptor superfamily members)

Notes

original target text: BCMA, BAFF-R (TNFRSF13C), TACI (TNFRSF13B) -- tri-antigen targeting

BCMA, TACI, and BAFF-R are three related receptors belonging to the tumor necrosis factor receptor superfamily, expressed predominantly on plasma cells, the antibody-producing cells that become malignant in multiple myeloma. All three receptors receive survival signals from the ligands APRIL and BAFF, promoting the persistence of long-lived plasma cells, including malignant ones. Chimeric antigen receptor (CAR) T-cell therapies engineered against a single one of these receptors, typically BCMA, have shown that tumor cells can escape treatment by reducing or losing expression of that one target. A construct designed to recognize all three receptors simultaneously addresses this vulnerability: a myeloma cell would need to downregulate multiple independent surface proteins at once to evade recognition, which is a much higher evolutionary barrier for the tumor. This mechanism is an allogeneic (donor-derived, 'off-the-shelf') cell therapy rather than one manufactured from the patient's own T cells, which has implications for how broadly and quickly it can be produced. Multi-antigen plasma-cell-directed CAR-T approaches are primarily relevant to multiple myeloma and other plasma-cell disorders where relapse after antigen-specific therapy is a recognized clinical problem.